STTK (Shattuck Labs) Total Inventories : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shattuck Labs Total Inventories?

Shattuck Labs's total inventories for the quarter that ended in Dec. 2024 was $0.00 Mil. Shattuck Labs's average total inventories from the quarter that ended in Sep. 2024 to the quarter that ended in Dec. 2024 was $0.00 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Shattuck Labs's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $1.29.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Shattuck Labs Total Inventories Historical Data

The historical data trend for Shattuck Labs's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shattuck Labs Total Inventories Chart

Shattuck Labs Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Inventories

Get a 7-Day Free Trial

Shattuck Labs Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Inventories	Get a 7-Day Free Trial															-	-	-	-	-

Shattuck Labs Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Shattuck Labs (NAS:STTK) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Shattuck Labs's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is

	Net-Net Working Capital Per Share (Q: Dec. 2024 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(72.987	+	0.75 * 0	+	0.5 * 0	-	11.423
-	0	-	0)	/	47.715
=	1.29

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Shattuck Labs's Days Inventory for the three months ended in Dec. 2024 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2024 )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Shattuck Labs's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2024 )	/	Average Total Inventories (Q: Dec. 2024 )
	=	0	/	0
	=	N/A

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Shattuck Labs's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	0	/	0
	=

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Shattuck Labs Total Inventories Related Terms

Thank you for viewing the detailed overview of Shattuck Labs's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Shattuck Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shattuck Labs Inc (NAS:STTK) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 W. 5th Street, Suite 1200, Austin, TX, USA, 78701

Website

https://www.shattucklabs.com

Shattuck Labs Inc is a clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. Its product candidate, SL-172154, has been rationally designed to simultaneously inhibit the CD47/SIRPa checkpoint interaction to restore an anti-tumor immune response and to activate the CD40 costimulatory receptor to bolster an immune response. Its product candidate, SL-279252, which is being developed in collaboration with Takeda Pharmaceuticals, or Takeda, has been rationally designed to simultaneously inhibit the PD-1/PD-L1 interaction and activate the OX40 receptor.

Executives

Redmile Group, Llc	director, 10 percent owner	ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Taylor Schreiber	director, officer: Chief Executive Officer	100 EUROPA DRIVE, CHAPEL HILL NC 27517
Tyler Brous	director	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Stephen Stout	officer: See Remarks	C/O SHATTUCK LABS, INC., 500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Andrew R Neill	officer: See Remarks	1018 W 11TH STREET, SUITE 100, AUSTIN TX 78703
George Golumbeski	director	C/O CELGENE CORP., 86 MORRIS AVENUE, SUMMIT NJ 07901
Abhinav A. Shukla	officer: Chief Technical Officer	500 W. 5TH STREET, SUITE 1200, AUSTIN TX 78701
Carrie Brownstein	director	500 W. 5TH ST., SUITE 1200, AUSTIN TX 78701
Erin Ator Thomson	officer: General Counsel	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Josiah Hornblower	director, 10 percent owner, officer: Chairman	3317 BOWMAN AVE, AUSTIN TX 78703
Neil W Gibson	director	C/O REGULUS THERAPEUTICS INC., 3545 JOHN HOPKINS COURT SUITE 210, SAN DIEGO CA 92121
Helen M Boudreau	director	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Arundathy N. Pandite	officer: Chief Medical Officer	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Victor Stone	director	1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Casi Deyoung	officer: Chief Business Officer	C/O MIRNA THERAPEUTICS, INC., 2150 WOODWARD ST., SUITE 100, AUSTIN TX 78744